ClinicalTrials.gov
Cure8 trial brief
Why This Matters
A phase 2 trial tested whether repurposing fenofibrate (a lipid-lowering PPAR-α agonist) added to mesalamine can reduce disease activity and improve quality of life in adults with mild-to-moderate ulcerative colitis.
If positive, this could offer a new adjunctive treatment option for people whose disease is managed with mesalamine.
Who Should Pay Attention
Adults with mild-to-moderate ulcerative colitis, gastroenterologists and IBD clinicians, clinical researchers studying drug repurposing or immune-pathway targets, and patients interested in non-biologic adjunctive therapies.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment70 participants
Study statusCompleted
Source depthTrial registry record
What To Know
The trial enrolled up to 70 participants at sites in Egypt and compared two arms: mesalamine alone (1 g three times daily) versus mesalamine plus fenofibrate (160 mg/day) for six months. The registered primary outcomes are change in disease activity index and improvement in health-related quality of life at 6 months.
The study excludes patients with severe UC, other IBD (including Crohn's), recent use of systemic or rectal steroids, immunosuppressives, or biologics, and significant liver or kidney abnormalities. That matters because the results apply to a selected group with mild-to-moderate UC on mesalamine.
Keep In Mind
This registry entry is a trial record from ClinicalTrials.gov (phase 2, completed). The entry gives study design, interventions, eligibility, and primary endpoints but does not include published results or full safety data.
Fenofibrate is primarily a lipid-lowering drug with reported anti-inflammatory effects in preclinical and other clinical contexts; any clinical benefit in UC would need peer-reviewed results and safety evaluation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorTanta University
Trial IDNCT05781698
Study typeInterventional
Trial phasePhase 2
Enrollment70 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 13, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Alpha Lipoic Acid in Ulcerative Colitis
Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate...
Dapagliflozin in Patients With Ulcerative Colitis
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.